Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 3, 2009, Pages 470-477

  Zakowski, Maureen F ^a   Hussain, Sanaa ^a,b   Pao, William ^a   Ladanyi, Marc ^a   Ginsberg, Michelle S ^a   Heelan, Robert ^a   Miller, Vincent A ^a   Rusch, Valerie W ^a   Kris, Mark G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GEFITINIB;

ABSTINENCE; ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG RESPONSE; DRUG TREATMENT FAILURE; EGFR GENE; FEMALE; GENE; GENE ACTIVATION; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MUCINOUS BRONCHIOLOALVEOLAR CARCINOMA; PREDICTION; SEQUENCE ANALYSIS; SMOKING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 62249156223     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:1103-1109.
3. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004;10:4227S-4232S.
4. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1 527-1537.
5. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-13311.
6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
7. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
9. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg. 2002;74:1640-1646.
10. Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and CT imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol. 2005;23:3279-3287.
11. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn. 2005;7:396-403.
12. Kang SM, Kang HJ, Shin JH, et al. Identical epidermal growth factor receptor mutations in adenosquamatous and squamous cell carcinomatous components of aadenosquamous carcinoma of the lung. Cancer. 2007;109:581-587.
13. Fineberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn. 2007;9:320-326.
14. Marchetti A, Buttitta F, Pellegrini S, et al. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol. 1996;179:254-259.
15. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17.
16. Blons H, Cote JF, Le Corre D, et al. Epidermal growth factor receptor mutation in lung cancer linked to bronchioloalveolar differentiation. Am J Surg Pathol. 2006;30:1309-1315.
17. Chantranuwat C, Sriuranpong V, Huapai N, et al. Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation. J Med Assoc Thai. 2005;88:S322-S329.
18. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res. 2005;11:1167-1173.
19. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857-865.
20. MacDonald LL, Yazdi HM. Fine-needle aspiration biopsy of bronchioloalveolar carcinoma. Cancer. 2001;93:29-34.
21. Auger M, Katz RL, Johnston DA. Differentiating cytological features of bronchioloalveolar carcinoma from adenocarcinoma of the lung in fine-needle aspirations: a statistical analysis of 27 cases. Diagn Cytopathol. 1997;16:253-257.
22. Silverman JF, Finley JL, Park HK, et al. Fine needle aspiration cytology of bronchioloalveolar-cell carcinoma of the lung. Acta Cytol. 1985;29:887-894.
23. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of theepidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513-2520.
24. Pao W, Miller VA, Kris MG. 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol. 2004;14:33-40.
25. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23:2556-2568.
26. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339-346.
27. Kim YH, Ishii G, Goto K, et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res. 2004;10:7311-7317.
28. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004. World Health Organization Classification of Tumours.
29. YatabeY, Kosaka T, Takahashi T, et al. EGFR mutation is specific forterminal respiratory unit type adenocarcinoma. Am J Surg Pathol. 2005;29:633-639.
30. Ohtsuka K, Ohnishi H, Fujiwara M, et al. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas. Cancer. 2007;109:741-750.
31. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer. 2004;19:208-212.
32. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copynumber and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798-3807.
33. Hirsch FR, Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-smallcell lung cancer. Curr Opin Oncol. 2005;17:118-122.
34. Cappuzzo F, Gregorc V, Rossi E, et al. Gefitinib in pre-treated non-small cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol. 2003;21:2658-2663.
35. Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) molecules as response predictive markers for Gefitinib (Iressa, ZD1 839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer. 2005;113:109-115.
36. Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell carcinoma: an immunohistochemical and fluorescence in situ hybridization study. Cancer. 2005;15:1265-1273.